Welcome to our dedicated page for Apollomics SEC filings (Ticker: APLM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Apollomics Inc. filings document the regulatory record of a foreign private issuer developing oncology therapies. Its Form 6-K reports furnish financial-results releases, clinical-development updates for vebreltinib (APL-101), material agreements and license matters, related-party convertible-note financing, collaboration updates, and operational-continuity disclosures.
The filing record also covers governance and control procedures, including director appointments and committee composition, auditor changes, registration-statement incorporation, and litigation-related disclosures. These filings place Apollomics' oncology pipeline, capital structure, public-company governance and risk matters into formal SEC-reporting categories.
Apollomics Inc. director Huang Ya-Chi filed an initial ownership report showing a holding of restricted stock units tied to the company’s Class A Ordinary Shares. The filing reflects 2,000 restricted stock units, vesting in four installments of 500 shares each during 2026. Each unit represents the right to receive one Class A Ordinary Share.
Apollomics Inc. director CHU YI-AN reported initial beneficial ownership consisting of restricted stock units linked to Class A Ordinary Shares. The filing shows 2,000 underlying shares associated with these restricted stock units. According to the vesting terms, 500 units vested on February 9, 2026, with additional 500-unit tranches vesting on March 15, 2026, June 15, 2026 and September 15, 2026. Each restricted stock unit represents a contingent right to receive one Class A Ordinary Share.
Apollomics Inc. director TSAI HSIEN-SHU reported an initial holding of restricted stock units that are linked to the company’s Class A Ordinary Shares. The position covers restricted stock units tied to 2,000 underlying Class A Ordinary Shares held directly.
According to the footnotes, these restricted stock units vested with respect to 500 shares upon grant on February 9, 2026, with an additional 500 shares scheduled to vest on each of March 15, 2026, June 15, 2026 and September 15, 2026. Each unit represents a contingent right to receive one Class A Ordinary Share.
Apollomics Inc. director Jan Chen-Huan reported initial beneficial ownership of 2,000 Restricted Stock Units (RSUs), each tied to one Class A Ordinary Share. The RSUs vested with respect to 500 shares on February 9, 2026, with additional 500-share tranches scheduled on March 15, 2026, June 15, 2026 and September 15, 2026. Each RSU represents a contingent right to receive one Class A Ordinary Share, and the position is held directly.
Apollomics Inc. director and COO Chen Yi-Kuei filed an initial Form 3 reporting his equity holdings. He directly holds restricted stock units covering 20,000 Class A Ordinary Shares, vesting in four installments of 5,000 shares each during 2026. Each unit represents the right to receive one share. Through Maxpro Investment Co., Ltd., he is attributed 101,248 Class A Ordinary Shares and warrants exercisable for 3,823 Class A Ordinary Shares at an adjusted exercise price of $1,150.00 per full share, or $11.50 per warrant. He disclaims beneficial ownership of the Maxpro-held securities except to the extent of his pecuniary interest.
Apollomics Inc. disclosed initial holdings for Chief Financial Officer Lin Peter Kuan-How, showing 40,000 Restricted Stock Units tied to Class A Ordinary Shares. The RSUs vest in stages: 10,000 shares vested upon grant on February 9, 2026, with an additional 10,000 vesting on each of March 15, 2026, June 15, 2026 and September 15, 2026. Each RSU represents a contingent right to receive one Class A Ordinary Share, and the position is reported as directly owned.
Apollomics Inc. registers the resale of 279,775 Class A ordinary shares for selling securityholders.
The shares were issued under subscription agreements dated September 2, 2025 and are being registered to permit the selling securityholders to offer and sell the PIPE Shares from time to time after effectiveness. The Company will not receive proceeds from resales and will pay registration expenses.
Apollomics Inc. reports that it has terminated its development and license agreement with Edison Oncology Holding Corporation covering APL-122, an oral, irreversible pan-ErbB inhibitor targeting EGFR, HER2 and HER4 for ErbB-positive cancers with central nervous system metastases. The company states it ended the collaboration effective immediately based on Edison’s failure to meet certain material performance and reporting obligations and is disputing any outstanding payment claims.
Apollomics indicates that it does not expect this termination to have a material adverse effect on its overall financial condition or results of operations, and notes that information about the termination is being incorporated by reference into its existing registration statements.
Apollomics Inc. (APLM) reported that it has entered into a settlement agreement to fully resolve legal proceedings in the Grand Court of the Cayman Islands brought by two minority investors. The dispute arose from claims filed on July 22, 2024, related to the requested redemption of certain preferred shares before Apollomics completed its 2023 public merger with Maxpro Capital Acquisition Corporation. A stay order had previously been issued on September 12, 2025, and the parties are now in the process of submitting the settlement for court approval to conclude the litigation. The information about this settlement is also being incorporated by reference into Apollomics’ registration statements on Form S-8 and Form F-3.
Apollomics, Inc. reported a change in its Board of Directors. On November 16, 2025, Mr. Po-Jen Hsueh resigned from the Board, with the company stating that his resignation was not related to any disagreement with the company.
On the same date, Dr. Ya-Chi (Claudia) Huang was appointed to the Board to fill the resulting vacancy and will also serve on the Audit Committee and the Nominating and Corporate Governance Committee. Following recent appointments, the Board now has seven members, five of whom are described as independent directors.
Dr. Huang brings experience in biotechnology investment, corporate governance, and R&D, including roles at Maxpro Ventures, Diamond Biofund, Fubon Securities, and multiple research institutions. The company also issued a press release on November 17, 2025 describing these board and committee changes, which is included as an exhibit.